ß-cell specific overexpression of suppressor of cytokine signalling-3 does not protect against multiple low dose streptozotocin induced type 1 diabetes in mice
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Standard
ß-cell specific overexpression of suppressor of cytokine signalling-3 does not protect against multiple low dose streptozotocin induced type 1 diabetes in mice. / Börjesson, A; Rønn, S G; Karlsen, A E; Billestrup, Nils; Sandler, S.
I: Immunology Letters, Bind 136, Nr. 1, 30.04.2011, s. 74-9.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - ß-cell specific overexpression of suppressor of cytokine signalling-3 does not protect against multiple low dose streptozotocin induced type 1 diabetes in mice
AU - Börjesson, A
AU - Rønn, S G
AU - Karlsen, A E
AU - Billestrup, Nils
AU - Sandler, S
N1 - Copyright © 2011 Elsevier B.V. All rights reserved.
PY - 2011/4/30
Y1 - 2011/4/30
N2 - We investigated the impact of ß-cell specific overexpression of suppressor of cytokine signalling-3 (SOCS-3) on the development of multiple low dose streptozotocin (MLDSTZ) induced Type 1 diabetes and the possible mechanisms involved. MLDSTZ treatment was administered to RIP-SOCS-3 transgenic and wild-type (wt) mice and progression of hyperglycemia monitored. Isolated islets from both strains were exposed to human IL-1ß (25U/ml) or a combination of human IL-1ß (25U/ml) and murine IFN-¿ (1000U/ml) for 24h or 48h and we investigated the expression of IL-1 receptor antagonist (IL-1Ra) mRNA in islet cells and secretion of IL-1Ra into culture medium. MLDSTZ treatment caused gradual hyperglycemia both in the wt mice and in the transgenic mice with the latter tending to be more sensitive. In vitro experiments on wt and transgenic islets did not reveal any differences in sensitivity to damaging effects of STZ. Exposure of wt islets to IL-1ß or IL-1ß+IFN-¿ seemed to lead to a failing IL-1Ra response from SOCS-3 transgenic islets. It could be that an increased expression of a possible protective molecule against ß-cell destruction may lead to a dampered response of another putative protective molecule. This may have counteracted a protective effect against MLDSTZ in SOCS-3 transgenic mice.
AB - We investigated the impact of ß-cell specific overexpression of suppressor of cytokine signalling-3 (SOCS-3) on the development of multiple low dose streptozotocin (MLDSTZ) induced Type 1 diabetes and the possible mechanisms involved. MLDSTZ treatment was administered to RIP-SOCS-3 transgenic and wild-type (wt) mice and progression of hyperglycemia monitored. Isolated islets from both strains were exposed to human IL-1ß (25U/ml) or a combination of human IL-1ß (25U/ml) and murine IFN-¿ (1000U/ml) for 24h or 48h and we investigated the expression of IL-1 receptor antagonist (IL-1Ra) mRNA in islet cells and secretion of IL-1Ra into culture medium. MLDSTZ treatment caused gradual hyperglycemia both in the wt mice and in the transgenic mice with the latter tending to be more sensitive. In vitro experiments on wt and transgenic islets did not reveal any differences in sensitivity to damaging effects of STZ. Exposure of wt islets to IL-1ß or IL-1ß+IFN-¿ seemed to lead to a failing IL-1Ra response from SOCS-3 transgenic islets. It could be that an increased expression of a possible protective molecule against ß-cell destruction may lead to a dampered response of another putative protective molecule. This may have counteracted a protective effect against MLDSTZ in SOCS-3 transgenic mice.
KW - Animals
KW - Cells, Cultured
KW - Diabetes Mellitus, Experimental
KW - Diabetes Mellitus, Type 1
KW - Gene Expression Regulation
KW - Hyperglycemia
KW - Insulin-Secreting Cells
KW - Mice
KW - Mice, Inbred C57BL
KW - Mice, Transgenic
KW - Receptor, Interferon alpha-beta
KW - Streptozocin
KW - Suppressor of Cytokine Signaling Proteins
U2 - 10.1016/j.imlet.2010.12.007
DO - 10.1016/j.imlet.2010.12.007
M3 - Journal article
C2 - 21237203
VL - 136
SP - 74
EP - 79
JO - Immunology Letters
JF - Immunology Letters
SN - 0165-2478
IS - 1
ER -
ID: 33902983